Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Roger, Burkinshaw"'
Autor:
Diana Greenfield, Roger Burkinshaw, J Fearnside, Jenny Freeman, John A. Snowden, Catherine Handforth, Janet E. Brown, Robert E. Coleman
Publikováno v:
Supportive Care in Cancer. 29:1145-1145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8e3938a3636e91346b2c26135cdcd53
https://doi.org/10.1007/s00520-020-05893-0
https://doi.org/10.1007/s00520-020-05893-0
Autor:
Peter Barrett-Lee, Victoria Liversedge, M. Gil, Caroline Wilson, Robert Grieve, D. Dodwell, Roger Burkinshaw, Helen Marshall, David Cameron, Emma Rathbone, Samantha Hinsley, Richard Bell, Diana Ritchie, M. Keane, Robert E. Coleman
Publikováno v:
The Lancet Oncology. 15:997-1006
Summary Background The role of adjuvant bisphosphonates in early breast cancer is uncertain. We therefore did a large randomised trial to investigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-risk patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440de9c767557fa85d8c0daadf72f6db
https://doi.org/10.1016/s1470-2045(14)70302-x
https://doi.org/10.1016/s1470-2045(14)70302-x
Autor:
Robert E, Coleman, Helen, Marshall, David, Cameron, David, Dodwell, Roger, Burkinshaw, Maccon, Keane, Miguel, Gil, Stephen J, Houston, Robert J, Grieve, Peter J, Barrett-Lee, Diana, Ritchie, Julia, Pugh, Claire, Gaunt, Una, Rea, Jennifer, Peterson, Claire, Davies, Victoria, Hiley, Walter, Gregory, Richard, Bell, Jill, Bishop
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
A b s t r ac t Background Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068813494c64181284eb1805b333cc57
https://doi.org/10.1056/nejmoa1105195
https://doi.org/10.1056/nejmoa1105195
Autor:
Roger Burkinshaw, M. Gil, M. Keane, Diana Ritchie, S J Marshall, Matthew C Winter, Duncan Wheatley, H. Thorpe, David Cameron, David Dodwell, José Luís Passos-Coelho, Richard Bell, Robert E. Coleman
Publikováno v:
British Journal of Cancer
Coleman, R E, Winter, M C, Cameron, D, Bell, R, Dodwell, D, Keane, M M, Gil, M, Ritchie, D, Passos-Coelho, J L, Wheatley, D, Burkinshaw, R, Marshall, S J, Thorpe, H 2010, ' The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response : exploratory evidence for direct anti-tumour activity in breast cancer ', British Journal of Cancer, vol. 102, no. 7, pp. 1099-105 . https://doi.org/10.1038/sj.bjc.6605604
Coleman, R E, Winter, M C, Cameron, D, Bell, R, Dodwell, D, Keane, M M, Gil, M, Ritchie, D, Passos-Coelho, J L, Wheatley, D, Burkinshaw, R, Marshall, S J, Thorpe, H 2010, ' The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response : exploratory evidence for direct anti-tumour activity in breast cancer ', British Journal of Cancer, vol. 102, no. 7, pp. 1099-105 . https://doi.org/10.1038/sj.bjc.6605604
BACKGROUND: Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd017bf07aca48dfa4417643cf3959e
https://doi.org/10.1038/sj.bjc.6605604
https://doi.org/10.1038/sj.bjc.6605604
Autor:
Claire Davies, Geraldine A. Matthews, Robert E. Coleman, Vicky Hiley, Roger Burkinshaw, H Marshall
Publikováno v:
Trials
Trials, Vol 12, Iss Suppl 1, p A78 (2011)
Trials, Vol 12, Iss Suppl 1, p A78 (2011)
Methods Determining how academic clinical trials units can optimise data quality via central monitoring methods is an important factor in trial management. In the AZURE trial, it became apparent from site monitoring that the endpoint dates as defined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d16d6381b3a8cc81693e40a25103d42
https://doi.org/10.1186/1745-6215-12-s1-a78
https://doi.org/10.1186/1745-6215-12-s1-a78
Autor:
Roger Burkinshaw, M. Gil, Robert E. Coleman, E.J. Woodward, M. Keane, Claire Davies, Richard Bell, Stephen Houston, D. Dodwell, Robert Grieve, Julia Brown, Duncan P. Cameron, H. Thorpe, Peter Barrett-Lee
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2011, 127 (2), pp.429-438. ⟨10.1007/s10549-011-1429-y⟩
Breast Cancer Research and Treatment, Springer Verlag, 2011, 127 (2), pp.429-438. ⟨10.1007/s10549-011-1429-y⟩
International audience; The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84cd3639124ea84ca36840bb4d9edb8a
https://hal.archives-ouvertes.fr/hal-00621619/document
https://hal.archives-ouvertes.fr/hal-00621619/document
Autor:
Robert Coleman, Roger Burkinshaw, Matthew Winter, Helen Neville-Webbe, Jim Lester, Emma Woodward, Janet Brown
Publikováno v:
Expert opinion on drug safety. 10(1)
Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f229d5cf7670f47f30e8dc880f261db
https://pubmed.ncbi.nlm.nih.gov/21114419
https://pubmed.ncbi.nlm.nih.gov/21114419
Publikováno v:
Breast Cancer Online. 10
Most patients present with disease that appears to be confined to the breast. However, a significant proportion of women will go on to develop metastatic breast cancer with bone being the most frequent site of distant relapse. The bone microenvironme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc4cb91f80ce7d938fa823f4bcaee8c
https://doi.org/10.1017/s1470903107005147
https://doi.org/10.1017/s1470903107005147
Autor:
Adam Finn, R Lakshman, Gillian Race, Qibo Zhang, Craig Murdoch, Roger Burkinshaw, Konstantinos Arnaoutakis
Publikováno v:
University of Bristol-PURE
Immunization with conjugate pneumococcal vaccines induces significant primary and memory IgG anti-polysaccharide (PS) responses in serum. It can also induce mucosal responses in infants especially after a polysaccharide booster. However, it is unclea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4792db837c5577ca70b70c1d867cd914
https://pubmed.ncbi.nlm.nih.gov/15071283
https://pubmed.ncbi.nlm.nih.gov/15071283
Publikováno v:
The Pediatric infectious disease journal. 21(3)
Background. Serogroup C meningococcal conjugate polysaccharide vaccines have been reported to induce significant serum IgG antibodies and immunologic memory in infants. Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local muc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6fed42c734e6d78d14b24a968bbabc7
https://pubmed.ncbi.nlm.nih.gov/12005084
https://pubmed.ncbi.nlm.nih.gov/12005084